These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 25927031)

  • 41. Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention.
    Nouri M; Ratther E; Stylianou N; Nelson CC; Hollier BG; Williams ED
    Front Oncol; 2014; 4():370. PubMed ID: 25566507
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
    Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
    Cancer Res; 2000 Feb; 60(3):741-8. PubMed ID: 10676662
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic significance of neuroendocrine differentiation in prostate adenocarcinoma.
    Sagnak L; Topaloglu H; Ozok U; Ersoy H
    Clin Genitourin Cancer; 2011 Dec; 9(2):73-80. PubMed ID: 22035833
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of neuroendocrine cells in prostate cancer: a comprehensive review of current literature and subsequent rationale to broaden and integrate current treatment modalities.
    Lugnani F; Simone G; Biava PM; Ablin RJ
    Curr Med Chem; 2014; 21(9):1082-92. PubMed ID: 24304274
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/β-catenin signaling in prostate cancer cells.
    Ciarlo M; Benelli R; Barbieri O; Minghelli S; Barboro P; Balbi C; Ferrari N
    Int J Cancer; 2012 Aug; 131(3):582-90. PubMed ID: 22015967
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuroendocrine differentiation of prostate cancer: a review.
    Parimi V; Goyal R; Poropatich K; Yang XJ
    Am J Clin Exp Urol; 2014; 2(4):273-85. PubMed ID: 25606573
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of Neuroendocrine Prostate Cancers by the Ser/Arg Repetitive Matrix 4-Mediated RNA Splicing Network.
    Lee AR; Che N; Lovnicki JM; Dong X
    Front Oncol; 2018; 8():93. PubMed ID: 29666783
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells.
    Tawadros T; Alonso F; Jichlinski P; Clarke N; Calandra T; Haefliger JA; Roger T
    Endocr Relat Cancer; 2013 Feb; 20(1):137-49. PubMed ID: 23207293
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
    May M; Siegsmund M; Hammermann F; Loy V; Gunia S
    Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST).
    Zhu Y; Liu C; Cui Y; Nadiminty N; Lou W; Gao AC
    Prostate; 2014 Aug; 74(11):1086-94. PubMed ID: 24819501
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hyperactive mTOR induces neuroendocrine differentiation in prostate cancer cell with concurrent up-regulation of IRF1.
    Kanayama M; Hayano T; Koebis M; Maeda T; Tabe Y; Horie S; Aiba A
    Prostate; 2017 Nov; 77(15):1489-1498. PubMed ID: 28905415
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer.
    Dong B; Fan L; Wang Y; Chi C; Ma X; Wang R; Cai W; Shao X; Pan J; Zhu Y; Shangguan X; Xin Z; Hu J; Xie S; Kang X; Zhou L; Xue W
    Prostate; 2017 May; 77(13):1373-1380. PubMed ID: 28804908
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.
    Yuan TC; Veeramani S; Lin MF
    Endocr Relat Cancer; 2007 Sep; 14(3):531-47. PubMed ID: 17914087
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Focal Neuroendocrine Differentiation of Conventional Prostate Adenocarcinoma as a Prognostic Factor after Radical Prostatectomy: A Systematic Review and Meta-Analysis.
    Kardoust Parizi M; Iwata T; Kimura S; Janisch F; Abufaraj M; Karakiewicz PI; Enikeev D; Rapoport LM; Hutterer G; Shariat SF
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30893781
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neuroendocrine transdifferentiation of prostate carcinoma cells and its prognostic significance.
    Marcu M; Radu E; Sajin M
    Rom J Morphol Embryol; 2010; 51(1):7-12. PubMed ID: 20191113
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
    Cox ME; Deeble PD; Lakhani S; Parsons SJ
    Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neuroendocrine cells in prostate cancer.
    Amorino GP; Parsons SJ
    Crit Rev Eukaryot Gene Expr; 2004; 14(4):287-300. PubMed ID: 15663358
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
    Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
    Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The many faces of neuroendocrine differentiation in prostate cancer progression.
    Terry S; Beltran H
    Front Oncol; 2014; 4():60. PubMed ID: 24724054
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Understanding the mechanism underlying the acquisition of radioresistance in human prostate cancer cells.
    Murata K; Saga R; Monzen S; Tsuruga E; Hasegawa K; Hosokawa Y
    Oncol Lett; 2019 Jun; 17(6):5830-5838. PubMed ID: 31186811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.